Who's Got The Munchies? -Aurora Releases Cannabis Wafers

Louis O'Neill10 Oct 3min read

EDMONTON and HAMILTON, ON, Oct. 8, 2019 – Aurora Cannabis Inc. ("Aurora") (NYSE |TSX: ACB), the Canadian company defining the future of cannabis worldwide, and CTT Pharmaceutical Holdings, Inc., ("CTT") (OTC | CTTH) announced today the successful commercialization of CTT's cannabinoid-infused sublingual wafers. The new cannabis product line, a first of its kind, has been launched by Aurora in the Canadian medical cannabis market under the brand name "Dissolve Strips™"

Aurora has an ownership interest in CTT of approximately 9%, with a warrant allowing it to increase its stake to 42.5%, and access to CTT's sublingual wafers drug delivery technology, which is patent protected or patent pending in multiple jurisdictions.

"Aurora's Dissolve Strips™ provide unique advantages over other ingestible products due to their ease of administration, discrete nature and accurate dosage, that provides more rapid bioavailability of cannabinoids via sublingual use," said Terry Booth, CEO of Aurora. "This adds yet another innovative offering to our growing portfolio of high quality, medical products that we offer our patient base, and is testament to our industry leading ability to work with technology partners and regulators to bring new form factors to market rapidly."

CTT's CEO Cam Birge, added, "The product launch with Aurora of the Dissolve Strips™ is a major milestone for us that marks the transition of CTT from a technology development phase to a revenue generating phase. This is the culmination of years of hard work by our founder Dr. Modi and the entire CTT and Aurora product development teams."

We are very proud of this co-achievement and congratulate Aurora for the considerable efforts and product enhancements to bring Dissolve Strips™ to the cannabis market.

Cam Birge, CEO of CTT

Birge went on to say that "our sights, however, are set much higher. The next stage in our development will be the launch of a broader portfolio of unique products on a global scale. We have been working towards this, and I look forward to reporting on our progress in the coming quarters."

Orally Dissolvable Thin Film ("ODF") Wafers ("wafers" or "sublinguals") are a proprietary drug delivery mechanism in the form of paper-thin polymer films used as carriers for pharmaceutical agents that have the following benefits:

ODF Wafer is taken orally but does not require water or swallowing

ODF Wafers dissolve quickly in the oral cavity (5-15 seconds), with the active ingredient rapidly absorbed and diffused for direct access to the bloodstream.

ODF Wafers are suitable for a wide range of patients, including geriatric and pediatric patients who experience difficulty swallowing.

Disclaimer: Past performance is not an indicator of future performance.

Disclaimer: past performance is not an indicator of future performance

About Aurora

Headquartered in Edmonton, Alberta, Canada with funded capacity in excess of 625,000 kg per annum and sales and operations in 25 countries across five continents, Aurora is one of the world's largest and leading cannabis companies. Aurora is vertically integrated and horizontally diversified across every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis and hemp production, derivatives, high value-add product development, home cultivation, wholesale and retail distribution.

Highly differentiated from its peers, Aurora has established a uniquely advanced, consistent and efficient production strategy, based on purpose-built facilities that integrate leading-edge technologies across all processes, defined by extensive automation and customization, resulting in the massive scale production of high-quality consistent product. Designed to be replicable and scalable globally, our production facilities are designed to produce cannabis at significant scale, with high quality, industry-leading yields, and low-per gram production costs. Each of Aurora's facilities is built to meet European Union Good Manufacturing Practices ("EU GMP") standards. Certification has been granted to Aurora's first production facility in Mountain View County, the MedReleaf Markham facility, and its wholly owned European medical cannabis distributor Aurora Deutschland. All Aurora facilities are designed and built to the EU GMP standard.

I want to learn more about…

CannabisLatest Stock Picks

I want to learn more about…

CannabisLatest Stock Picks

The Green Fund is Asia Pacific's preeminent media house, positioned at the forefront of the global cannabis industry. Committed to driving the industry forward, we spotlight the sector from all angles, explore the companies and the players making headlines, and cover some of the biggest cannabis companies in the world.

Any financial product advice provided in this website is general in nature. Content on this website does not take into account the objectives, financial situation or needs of any person, or purport to be comprehensive or constitute investment advice and should not be relied upon as such. You should consult a professional adviser to help you form your own opinion of the information and on whether the information is suitable for your individual objectives and needs as an investor. Where necessary, you should obtain a Product Disclosure Statement relating to the product and consider it before making any decision about whether to acquire the product. Read More

The content of this website does not constitute an offer by any representative of The Green Fund to buy or sell any financial products or services. Accordingly, reliance should not be placed solely on the content of this website, including any reports or recommendations, as the basis for making an investment, financial or other decision.

Recipients should not act on any report or recommendation issued by The Green Fund without first consulting a professional advisor in order to ascertain whether the recommendation (if any) is appropriate, having regard to their investment objectives, financial situation and particular needs. Any opinions expressed are subject to change without notice and may not be updated by The Green Fund.

The Green Fund believes the information contained in this website is correct. All information, opinions, conclusions, estimates, reports or recommendations provided are included with due care to its accuracy; however, no representation or warranty is made as to their accuracy, completeness, or reliability.

The Green Fund disclaims all liability and responsibility for any direct or indirect loss, or damage, which may be incurred by any recipient through any information, omission, error, or inaccuracy contained within any report or recommendation.

The views expressed in any report or recommendation are those of the analyst writing the report and no part of the compensation received by the analyst is directly related to the inclusion of specific recommendations or opinions.

The Green Fund and / or its associates may hold interests in the entities mentioned in any posted report or recommendation.

The Green Fund, or its representatives, may have relationships with the companies mentioned in posted reports - for example, acting as corporate advisor, dealer, broker, or holder of principal positions. The Green Fund and / or its representatives may also transact in those securities mentioned in the report, in a manner not consistent with recommendations made in the report.

Any recommendations or opinions stated in a report are done so based on assumptions made by The Green Fund.

The information provided in any report and on which it is based may include projections and / or estimates which constitute forward-looking statements. These expressed beliefs of future performance, events, results, or returns may not eventuate and as such no guarantee of these future scenarios is given or implied by The Green Fund. Any forward looking statements are subject to uncertainties and risks that may mean those forecasts made by The Green Fund are materially different to actual events. Show Less